Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002282 · ClinicalTrials.gov registry record · NA

A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS

A NA study of HIV Infections and Candidiasis, Oral, sponsored by Pfizer.

Completed
Registry status
NA
Development phase
17
Study locations

NCT00002282 is a NA study of HIV Infections and Candidiasis, Oral that has completed, run by Pfizer. The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002282, a NA study of HIV Infections and Candidiasis, Oral, has completed, sponsored by Pfizer.

COMPLETED
Registry status
NA
Development phase
17
Study locations

Study Summary

To compare the efficacy, safety, and tolerance of fluconazole single daily capsule for 14 days versus clotrimazole troche 5 x daily for 14 days in the treatment of oropharyngeal candidiasis in patients with AIDS.

Interventions

  • DRUG Fluconazole
  • DRUG Clotrimazole

Study Locations (17)

California

  • Dr Robert Larsen - Los Angeles
  • Summitt Med Ctr / San Francisco Gen Hosp - Oakland
  • Davies Med Ctr - San Francisco
  • UCSF Hosp - San Francisco

New York

  • Cabrini Med Ctr - New York
  • Cornell Univ Med Ctr - New York
  • SUNY / Health Sciences Ctr at Stony Brook - Stony Brook

Connecticut

  • Saint Raphael's Hosp - New Haven

District of Columbia

  • George Washington Univ Med Ctr - Washington D.C.

Maryland

  • Johns Hopkins Hosp - Baltimore

Massachusetts

  • Univ Hosp - Boston

Missouri

  • Washington Univ School of Medicine - St Louis

New Jersey

  • Saint Michael's Med Ctr - Newark

Trial Details

FieldValue
Phase NA

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00002282

The ClinicalTrials.gov registry entry for NCT00002282 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Fluconazole is the first listed.

NCT00002282 reports 17 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00002282 about?

NCT00002282 is a clinical study titled "A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS". To compare the efficacy, safety, and tolerance of fluconazole single daily capsule for 14 days versus clotrimazole troche 5 x daily for 14 days in the treatment of oropharyngeal candidiasis in patients with AIDS.

What is the current status of trial NCT00002282?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002282 study?

This clinical trial studies the following conditions: HIV Infections, Candidiasis, Oral.

What interventions are being tested in trial NCT00002282?

The interventions under investigation include: Fluconazole (DRUG), Clotrimazole (DRUG).

Who is sponsoring clinical trial NCT00002282?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002282 being conducted?

This trial has 17 study locations across California, Connecticut, District of Columbia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.